Page last updated: 2024-12-05

dimethyl-4-toluidine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Dimethyl-4-toluidine, also known as N,N-dimethyl-p-toluidine, is a colorless to pale yellow liquid with a characteristic amine odor. It is a common organic compound used as an intermediate in the synthesis of dyes, pharmaceuticals, and other chemicals. Dimethyl-4-toluidine is synthesized by the reaction of p-toluidine with methanol in the presence of a catalyst. It is a strong base and can be readily protonated to form the corresponding ammonium salt. Dimethyl-4-toluidine has been studied for its potential applications in various fields, including organic synthesis, polymer chemistry, and materials science. It is also a valuable starting material for the preparation of other important compounds, such as 4-toluidine diazonium salt, which is used in the production of azo dyes.'

Cross-References

ID SourceID
PubMed CID7471
CHEMBL ID1462714
SCHEMBL ID28378
MeSH IDM0065387

Synonyms (69)

Synonym
AC-368
dimethyl-p-toluidine
n,n-dimethyl-4-methylaniline
p-methyl-n,n-dimethylaniline
n,n-dimethyl-p-toluidine
99-97-8
nsc1785
benzenamine,n,4-trimethyl-
n,4-trimethylaniline
p-n,n-trimethylaniline
n,n-dimethyl-p-tolylamine
nsc-1785
benzenamine, n,n,4-trimethyl-
p-toluidine, n,n-dimethyl-
n,n,4-trimethylaniline
ccris 1001
dimethyl-4-toluidine
p-(dimethylamino)toluene
dimetil-p-toluidina [italian]
p,n,n-trimethylaniline
nsc 1785
einecs 202-805-4
NCGC00091397-01
4,n,n-trimethylaniline, 99%
4-dimethylaminotoluene
D0807
MLS001050174
smr001216586
FT-0656134
NCGC00091397-02
NCGC00091397-03
dimethyl-(p-tolyl)-amine
n,n-dimethyl-para-toluidine
NCGC00254201-01
cas-99-97-8
tox21_201370
NCGC00258922-01
tox21_300062
dtxcid401832
dtxsid0021832 ,
dimetil-p-toluidina
ec 202-805-4
n,n,4-trimethylbenzenamine
unii-s8xc5939vu
hsdb 8202
s8xc5939vu ,
FT-0629511
FT-0636092
AKOS015915159
CHEMBL1462714
SCHEMBL28378
dimethyltolylamine [inci]
1-(dimethylamino)-4-methylbenzene
dimethyltolylamine
n,n-dimethyl-p-toluidine [iarc]
4-dimethylamino-1-methylbenzene
n,n-dimethyl-p-methylphenylamine
n,n-dimethyl-4-toluidine
benzeneamine,n,n,4-trimethyl-
W-100002
4,n,n-trimethylaniline
mfcd00008316
4,n,n-trimethylaniline, purum, >=98.0% (gc)
E75885
Q2051705
nl 65-100
n,n-dibenzyl-1,4,10,13-tetraoxa-7,16-diazacyclooctadecane
EN300-7266829
Z1002998236

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" It is verified that DMPT's toxic effect on cell cultures is dose-related; a delay in the cell replication cycle is induced in vitro."( High-performance liquid chromatography assay of N,N-dimethyl-p-toluidine released from bone cements: evidence for toxicity.
Cavedagna, D; Ciapetti, G; Granchi, D; Pizzoferrato, A; Stea, S; Visentin, M; Zolezzi, C, 1997
)
0.3
" This study aimed to examine possible time-dependent toxic effects of provisional crown and bridge restoration materials, manipulated intraorally or extraorally, on epithelia cells."( Cytotoxicity of provisional crown and bridge restoration materials: an in vitro study.
Dogan, A; Ergün, G; Karaoglu, T; Mutlu-Sagesen, L, 2001
)
0.31

Bioavailability

ExcerptReferenceRelevance
" At lower oral doses, [14C]DMPT-derived radioactivity was well absorbed and rapidly excreted, primarily in urine."( Disposition of [14C]N,N-dimethyl-p-toluidine in F344 rats and B6C3F1 mice.
Dix, KJ; Ghanbari, K; Hedtke-Weber, BM, 2007
)
0.34

Dosage Studied

ExcerptRelevanceReference
" Mean body weights of all surviving dosed groups of males and females were significantly less than those of the vehicle controls."( Toxicology and carcinogenesis studies of N,N-dimethyl-p-toluidine (CAS No. 99-97-8) in F344/N rats and B6C3F1/N mice (gavage studies).
, 2012
)
0.38
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (10)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
RAR-related orphan receptor gammaMus musculus (house mouse)Potency2.43370.006038.004119,952.5996AID1159521
GLI family zinc finger 3Homo sapiens (human)Potency15.26170.000714.592883.7951AID1259369
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency39.81070.011212.4002100.0000AID1030
thyroid stimulating hormone receptorHomo sapiens (human)Potency1.58490.001318.074339.8107AID926; AID938
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency16.95030.001022.650876.6163AID1224838; AID1224839; AID1224893
pregnane X nuclear receptorHomo sapiens (human)Potency54.48270.005428.02631,258.9301AID1346982
estrogen nuclear receptor alphaHomo sapiens (human)Potency61.21430.000229.305416,493.5996AID743069; AID743079
peroxisome proliferator activated receptor gammaHomo sapiens (human)Potency50.11870.001019.414170.9645AID588537
aryl hydrocarbon receptorHomo sapiens (human)Potency58.57370.000723.06741,258.9301AID743085; AID743122
cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_aHomo sapiens (human)Potency61.37000.001723.839378.1014AID743083
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (59)

TimeframeStudies, This Drug (%)All Drugs %
pre-19908 (13.56)18.7374
1990's16 (27.12)18.2507
2000's26 (44.07)29.6817
2010's9 (15.25)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 10.47

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index10.47 (24.57)
Research Supply Index4.14 (2.92)
Research Growth Index4.62 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (10.47)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (1.61%)6.00%
Case Studies6 (9.68%)4.05%
Observational0 (0.00%)0.25%
Other55 (88.71%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]